EU Commission signs contract for another Covid-19 drug

by time news

The drug is intended to be used to treat Covid patients who do not need oxygen but who are at risk of serious illness. Approval is still pending.

Die I-Commission has signed a framework agreement for the joint acquisition of a Covid-19 drug from the pharmaceutical company Eli Lilly. 18 EU countries took part in the joint purchase of 220,000 treatments of a drug with so-called monoclonal antibodies, the Brussels authority announced on Tuesday.

It is the combination of the two monoclonal antibodies Bamlanivimab and Etesevimab for the treatment of Covid patients who do not need oxygen, but who are at risk of serious illness. Monoclonal antibodies are made in the laboratory and are designed to disable the virus after infection.

The European Medicines Agency (EMA) is currently examining approval of the antibody cocktail. The question of who is among the 18 participating countries initially remained open. The EU-Commission has already signed contracts for other drugs.

(APA/dpa)

You may also like

Leave a Comment